Analyst Price Targets — DCTH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 13, 2026 11:17 am | — | BTIG | $17.00 | $13.01 | TheFly | Delcath Systems price target raised to $17 from $16 at BTIG |
| February 26, 2026 6:15 pm | — | Evercore ISI | $27.00 | $9.17 | StreetInsider | Delcath Systems (DCTH) PT Lowered to $27 at Clear Street |
| February 26, 2026 4:54 pm | Marie Thibault | BTIG | $19.00 | $9.17 | StreetInsider | Delcath Systems (DCTH) PT Lowered to $19 at BTIG |
| October 21, 2025 1:03 pm | Chase Knickerbocker | Craig-Hallum | $20.00 | $11.42 | TheFly | Delcath Systems price target lowered to $20 from $24 at Craig-Hallum |
| October 20, 2025 2:12 pm | — | H.C. Wainwright | $30.00 | $10.97 | TheFly | Delcath Systems price target lowered to $30 from $31 at H.C. Wainwright |
| March 7, 2025 11:11 am | — | H.C. Wainwright | $24.00 | $13.00 | TheFly | Delcath Systems price target raised to $24 from $22 at H.C. Wainwright |
| May 15, 2024 7:22 am | Swayampakula Ramakanth | H.C. Wainwright | $22.00 | $7.54 | StreetInsider | Delcath Systems (DCTH) PT Raised to $22 at H.C. Wainwright |
Latest News for DCTH
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to four individuals whose employment commenced in either May 2026 or June…
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the first patient has been dosed at the European Institute of Oncology (IEO) in Milan, Italy in its global Phase 2 clinical trial evaluating HEPZATO in combination with standard of care (SOC) treatment for liver-dominant…
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of two investigator-initiated trials-in-progress abstracts on May 21, 2026. These abstracts will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The…
On May 22, 2026, Delcath Systems Inc (DCTH) shares fell 3.8%, bringing the current price to $11.02. The stock's performance over the last year has been disappoi
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to four individuals whose employment commenced in either March 2026 or…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DCTH.
U.S. House Trading
No House trades found for DCTH.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.